Next Article in Journal
In This Issue of Current Oncology
Previous Article in Journal
An Updated Review on the Efficacy of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue s1
10.3747/co.v16i0.457
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Safety of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancertissues

by
S. Sehdev
*,
G. Martin
,
L. Sideris
,
W. Lam
and
S. Brisson
1
The Oncology Group, William Osler Health Centre, Brampton, ON, Canada
2
Hôpital Notre Dame, University of Montreal, Montreal, QC, Canada
3
Maisonneuve–Rosemont Hospital, University of Montreal, Montreal, QC, Canada
4
Burnaby Hospital Regional Cancer Centre, Burnaby, BC, Canada
5
Hôpital de Gatineau, Gatineau, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(s1), 14-23; https://doi.org/10.3747/co.v16i0.457
Submission received: 4 April 2009 / Revised: 14 May 2009 / Accepted: 12 June 2009 / Published: 1 July 2009

Abstract

Postmenopausal patients with hormone-sensitive early breast cancer are typically treated with adjuvant endocrine therapy, which significantly reduces the risk of recurrence. Because treatment is of a long duration, side effects from adjuvant therapy can be problematic. The aromatase inhibitors (AIs) are replacing tamoxifen as first-line treatment agents for early breast cancer. Here, we present the side-effect data associated with AIs in relation to bone, gynecologic, and cardiovascular health and to arthralgia and myalgia. Although AIs have been shown to decrease bone density, increase arthralgia, and affect vaginal health, these adverse events are usually manageable, and several strategies can be followed to improve quality of life in women on AI treatment. To optimize adherence to therapy. It is important that these issues are addressed so that women can benefit from treatment.
Keywords: adjuvant endocrine therapy; breast cancer; aromatase inhibitors; side effects adjuvant endocrine therapy; breast cancer; aromatase inhibitors; side effects

Share and Cite

MDPI and ACS Style

Sehdev, S.; Martin, G.; Sideris, L.; Lam, W.; Brisson, S. Safety of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancertissues. Curr. Oncol. 2009, 16, 14-23. https://doi.org/10.3747/co.v16i0.457

AMA Style

Sehdev S, Martin G, Sideris L, Lam W, Brisson S. Safety of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancertissues. Current Oncology. 2009; 16(s1):14-23. https://doi.org/10.3747/co.v16i0.457

Chicago/Turabian Style

Sehdev, S., G. Martin, L. Sideris, W. Lam, and S. Brisson. 2009. "Safety of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancertissues" Current Oncology 16, no. s1: 14-23. https://doi.org/10.3747/co.v16i0.457

APA Style

Sehdev, S., Martin, G., Sideris, L., Lam, W., & Brisson, S. (2009). Safety of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancertissues. Current Oncology, 16(s1), 14-23. https://doi.org/10.3747/co.v16i0.457

Article Metrics

Back to TopTop